Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Tilray Brands Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.5 (market cap $31.07B), while Tilray Brands Inc trades at $3.1 (market cap $481.79M). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 64.5× Tilray Brands Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| GEHC | TLRY | |
|---|---|---|
Market Cap | $31.07B | $481.79M |
Volume | 3,443,020 | 4,056,443 |
Sector | Health | Health |
52-Week High | $88.16 | $16.80 |
52-Week Low | $59.48 | $3.14 |
Enterprise Value | $39.53B | $635.71M |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 31 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Tilray Brands (TLRY) trades at $3.27, down 2.68% on the day and near 52-week lows, with bearish technical signals dominating. The company reported $821 million in revenue for 2025 but posted a massive $2.19 billion net loss due to impairment charges. Recent earnings misses and negative cash flow from operations highlight ongoing profitability challenges despite analyst consensus pointing to significant upside potential.
TLRY presents a high-risk opportunity with substantial analyst price target divergence. While valuation metrics appear attractive (P/S 0.4x, P/B 0.3x), persistent losses and cash burn require careful monitoring. The stock's fate hinges on cannabis reform progress and the company's ability to achieve sustainable profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
